Project Grant R01CA293091
Award Date
9/17/24
Completion Date
8/31/29
Dollars Obligated
$690K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) totaling $459,867 provides funding to develop and clinically validate natural language processing methods, particularly neural language models, to extract and monitor immune-related adverse events (IRAEs) from electronic health records (EHRs) for cancer patients treated with immune checkpoint inhibitors. The project aims to improve IRAE identification, severity...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $127,629 to Harvard T.H. Chan School of Public Health to conduct research on the role of human leukocyte antigen (HLA) variations in immune response and the efficacy of immune checkpoint inhibitor (ICI) monotherapy for non-small cell lung cancer (NSCLC). The key objectives are to: 1) identify the mechanisms linking germline and somatic HLA variations, somatic mutations,...
This $754,511 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting research to discover host genetic factors that affect response to immune checkpoint inhibitor (ICI) cancer therapies. The principal investigators at the Jackson Laboratory are using a mouse experimental platform to systematically map quantitative trait loci (QTLs) that influence ICI response, with a focus on defining the genetic mechanisms behind key epistatic...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) to The Johns Hopkins University will support research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The $547,945 award, running from January 1, 2025 to December 31, 2029, will involve investigating how biological factors such as prior cardiac injury, age, and sex modulate the risk of this potentially fatal immune-related adverse event. The research will...
This $755,970 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to address key challenges in the care of patients who develop immune checkpoint inhibitor-associated acute interstitial nephritis (ICI-AIN). The goals are to: Test the use of the biomarker CXCL9 to accurately diagnose ICI-AIN and predict response to corticosteroid therapy. This will be...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $684,367 to the Baylor College of Medicine to conduct research aimed at identifying new predictors of response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The key objectives are to: 1) Identify intratumoral microbiome profiles predictive of ICI response using whole-metagenome sequencing; 2) Characterize spatial immune...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding to support the computational research and platform development activities of a laboratory-based research specialist at the Cleveland Clinic Lerner College of Medicine. The key products and services delivered under this $212,567 award, spanning from September 2024 to August 2029, include: Computational analysis of cancer patient-derived next-generation...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
The National Cancer Institute (NCI) awarded a $2,104,477 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study resistance mechanisms and enhance response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The project aims to characterize the co-evolution of cancer and the immune system during immunotherapy in CNS metastases by profiling...
This $1,131,820 Project Grant awarded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will support research to characterize toxicities and health-related quality of life among diverse individuals receiving immune checkpoint inhibitors for metastatic cancer. The 5-year study, led by the University of Miami, aims to: 1) examine associations between patient characteristics and toxicities/quality of life, 2) identify...